About Aqemia
Aqemia is a Healthcare company based in Paris (France) founded in 2019 by Maximilien Levesque. Therapeutic molecules are discovered through AI and quantum physics integration. It operates in the Healthcare and Technology sectors. Aqemia has raised $102.82 million across 5 funding rounds from investors including Eurazeo, Bpifrance and Wendel. Its chief executive, as recorded, is Maximilien Levesque. Aqemia offers products and services including AI Drug Discovery Platform and Quantum Physics Algorithms. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery.
Company details
Aqemia was founded in 2019 in Paris, France, as a provider of AI-driven software combined with quantum physics for therapeutic molecule discovery. Small molecules are screened using AI-based technology to assess physical properties, supporting upstream processing and drug development. Therapeutic targets linked to specific diseases are identified. Operations focus on biotechnology and pharmaceuticals, aiding research in molecular screening and target validation across global collaborations.
- Headquarters Paris, France
- Founders Maximilien Levesque
- SectorsHealthcareTechnology
- Website aqemia.com
- Social LinkedIn X
- Total Equity Funding$102.82M (USD)
in 5 rounds
- Latest Funding Round$7.4M (USD), Grant
Apr 2025
- InvestorsEurazeo
& 5 more
Products & Services of Aqemia
Aqemia offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform and Quantum Physics Algorithms.
Uses AI and quantum physics to generate drug candidates rapidly.
Algorithms that produce data for early-stage drug discovery projects.
Funding Insights of Aqemia
Aqemia has successfully raised a total of $102.82M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $7.4 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $102.82M
- Total Rounds 5
- Last Round Grant — $7.4M
- First Round $1.1M
(Oct 2019)
- Investors Count 6
All 5 funding rounds of Aqemia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
6 investors in total: 6 institutional.
Investors in Aqemia
Aqemia has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Eurazeo, Bpifrance and Wendel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in technology startups through a global ecosystem. | cathayinnovation.com | |||
Private equity and funds of funds focused on industrial, media, energy, healthcare, biotechnology, and multiple sectors | 1704 | wendelgroup.com | Paris, France | |
Private equity and debt investments are managed across multiple sectors. | 1969 | eurazeo.com | Paris, France | |
Venture capital firm focused on early-stage investments | elaia.com | Paris, France | ||
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
| gouv.fr |
Investor details for Aqemia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aqemia
26 people are tracked at Aqemia (10 in leadership, 16 in team).
| Name | Role | Group |
|---|---|---|
Maximilien Levesque | Founder & CEO | Leadership |
Orianne Bornand | Head of Communications and Marketing | Leadership |
Emmanuelle Martiano Rolland | Co-Founder & COO | Leadership |
Théa Vu - Bignand | Head of Finance | Leadership |
Sylvain Sabi | VP Engineering | Leadership |
Nicolas Canouï | Head Of Drug Discovery Platform | Leadership |
Dr Veronique Birault Fmedsci | VP Translational Sciences | Leadership |
Ingrid Delval | Chief of Staff | Leadership |
Marina Moisan | Human Resources Business Partner & Projects | Leadership |
Coline le Grand | Chief Of Staff To The COO | Leadership |
Victor Noilhan | Research Scientist - In Silico Drug Discovery | Team |
Alexandre Bordat | CRO Manager | Team |
Mireia Ruiz Maymó | Program Lead | Team |
Mathilde Batisse | RPO International Senior Talent Hunter @aqemia | Team |
Lorien Benda | Team Lead | Team |
Christine Hans | Senior Talent Acquisition Specialist | Team |
Théau Debroise | Research Scientist - In Silico Drug Discovery | Team |
Marc Helbling | Software Engineer | Team |
Quentin Chamayou | Program Lead | Team |
Salete Baptista | Drug Hunter - Research Scientist For In Silico Drug Discovery | Team |
6 more people are available in the full profile.
Complete people profiles for Aqemia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aqemia
3 dated milestones of Aqemia across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Aqemia is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Grant, of $7.4M.
Web traffic of Aqemia
The website of Aqemia (aqemia.com) receives about 5.3K visits a month.
- Monthly visits5.3K
▼ 13.8% vs previous month
Websites whose visitors overlap most with Aqemia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aisuperior.com | 100% | 48.4K | #766,569 | View details | |
| iktos.ai | 32% | 10.3K | #2,187,641 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aqemia
Complete news archive for Aqemia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aqemia
Aqemia was founded in 2019.
Aqemia is headquartered in Paris, France.
Maximilien Levesque is the CEO of Aqemia, as recorded in our data. They have also founded this company.
Aqemia is a funded company, having raised a total of $102.82M across 5 funding rounds to date. The company's 1st funding round was a Seed of $1.1M, raised on Oct 2019.
Aqemia was founded in 2019 in Paris, France, as a provider of AI-driven software combined with quantum physics for therapeutic molecule discovery. Small molecules are screened using AI-based technology to assess physical properties, supporting upstream processing and drug development. Therapeutic targets linked to specific diseases are identified. Operations focus on biotechnology and pharmaceuticals, aiding research in molecular screening and target validation across global collaborations.
Aqemia offers AI Drug Discovery Platform and Quantum Physics Algorithms.
Aqemia has 6 investors. Key investors include Eurazeo, Bpifrance, Wendel, gouv.fr, and Cathay Innovation.